- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00680225
Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma
April 10, 2017 updated by: New England Retina Associates
Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma
To report preliminary results on safety and tolerability of intravitreal injection of Ranibizumab (Lucentis) combined with Transpupillary Thermotherapy (TTT)+ Indocyanine Green (ICG)-based photodynamic therapy (PDT) in the treatment of choroidal melanoma.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Connecticut
-
Hamden, Connecticut, United States, 06518
- New England Retina Associates
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age > 18 yo.
- Primary pigmented or amelanotic choroidal melanoma measurement of 16 mm or less in the largest vessel diameter and 6 mm or less in the apical height.
- Location of the tumor posterior to the equator.
- Documented growth by A/B scan.
- Risk factor for metastasis (thickness greater than 2 mm, symptoms, tumor margin at the optic disc)
- Ability to provide inform consent.
- Comply with the study assessment for the cooperation of the study.
Exclusion Criteria:
- Pregnancy or lactation.
- Premenopausal women not using adequate contraception; surgical sterilization or use of oral contraception, barrier contraception with either a condom or diaphragm or in conjunction with spermicidal gel, an IUD or contraceptive hormon implant or patch.
- Current infection or inflammation in either eye.
- Extension of tumor into the orbit.
- Retinal spread or metastatic disease.
- Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated.
- Any known allergy to any of the components to be used in the study.
- Participation in another simultaneous medical investigation or trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lucentis Injection
Intravitreal injection of ranibizumab (0.5mg) once a month for 6 months and transpupillary thermotherapy enhanced with Indocyanine Green (ICG) dye, once or twice starting at 2nd month.
|
Intravitreal injection of ranibizumab (0.5mg) once a month for 6 months and transpupillary thermotherapy enhanced with Indocyanine Green (ICG) dye, once or twice starting at 2nd month.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean Tumor Thickness
Time Frame: 12 mo
|
12 mo
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Visual Acuity Changes
Time Frame: 12 mo
|
12 mo
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2007
Primary Completion (Actual)
July 1, 2012
Study Completion (Actual)
July 1, 2012
Study Registration Dates
First Submitted
May 15, 2008
First Submitted That Met QC Criteria
May 15, 2008
First Posted (Estimate)
May 20, 2008
Study Record Updates
Last Update Posted (Actual)
April 12, 2017
Last Update Submitted That Met QC Criteria
April 10, 2017
Last Verified
April 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Melanoma
- Physiological Effects of Drugs
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Ranibizumab
Other Study ID Numbers
- FVF4290s
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Choroidal Melanoma
-
Aura BiosciencesCompletedOcular Melanoma | Uveal Melanoma | Choroidal MelanomaUnited States
-
Aura BiosciencesActive, not recruitingOcular Melanoma | Uveal Melanoma | Choroidal MelanomaUnited States
-
Jonsson Comprehensive Cancer CenterCompleted
-
Jonsson Comprehensive Cancer CenterCompletedOcular Melanoma | Uveal Melanoma | Choroidal MelanomaUnited States
-
New England Retina AssociatesGenentech, Inc.CompletedChoroidal MelanomaUnited States
-
New England Retina AssociatesCompleted
-
Institut CurieCompleted
-
Institut CurieCompletedChoroidal Melanoma, DiffuseFrance
-
Aura BiosciencesTerminatedChoroidal Melanoma | Indeterminate LesionsUnited States
-
Aura BiosciencesRecruitingChoroidal Melanoma | Indeterminate Lesions of EyeUnited States
Clinical Trials on Ranibizumab injection and TTT - ICG based
-
New England Retina AssociatesCompleted
-
Anders KvantaCompletedNeovascular Age-related Macular DegenerationSweden
-
Shanglei LiuRecruitingPerfusion; ComplicationsUnited States
-
Genentech, Inc.CompletedMacular Edema | Retinal Vein Occlusion
-
Genentech, Inc.CompletedMacular Edema | Retinal Vein Occlusion
-
Ostfold Hospital TrustOslo University HospitalRecruitingCholecystitis | Gall StoneNorway
-
Zhujiang HospitalRecruiting
-
Region SkaneNot yet recruitingLymphedema | Endometrial Cancer | Sentinel Lymph NodeSweden
-
Peter A Campochiaro, MDGenentech, Inc.CompletedMacular Edema | Retinal Vein OcclusionUnited States
-
University of PennsylvaniaCompleted